These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31795962)

  • 41. Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy.
    Chou HH; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Yu MC; Lo YF; Dabora MA; Chang HK; Lin YC; Ueng SH; Chen SC
    Biomed J; 2019 Feb; 42(1):66-74. PubMed ID: 30987708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
    Cao YW; Liu Y; Dong Z; Guo L; Kang EH; Wang YH; Zhang W; Niu HT
    Urol Oncol; 2018 Jun; 36(6):311.e15-311.e25. PubMed ID: 29657088
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic significance of carbonic anhydrase IX overexpression in stage III non-small cell lung cancer patients after neoadjuvant treatment.
    Ibis K; Saglam S; Saglam EK; Firat P; Yilmazbayhan D; Toker A; Ozkan B; Hancer VS; Buyukdogan M; Disci R; Pilanci KN
    Pathol Res Pract; 2018 Sep; 214(9):1291-1296. PubMed ID: 30029935
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
    Kimbung S; Markholm I; Bjöhle J; Lekberg T; von Wachenfeldt A; Azavedo E; Saracco A; Hellström M; Veerla S; Paquet E; Bendahl PO; Fernö M; Bergh J; Loman N; Hatschek T; Hedenfalk I;
    Int J Cancer; 2018 Feb; 142(3):618-628. PubMed ID: 28940389
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis.
    Martins SF; Amorim R; Viana-Pereira M; Pinheiro C; Costa RF; Silva P; Couto C; Alves S; Fernandes S; Vilaça S; Falcão J; Marques H; Pardal F; Rodrigues M; Preto A; Reis RM; Longatto-Filho A; Baltazar F
    BMC Cancer; 2016 Jul; 16():535. PubMed ID: 27460659
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Multicenter Study of the Impact of Body Mass Index (BMI) on the incidence of Pathologic Complete Response (pCR) Among Saudi Patients with locally advanced Breast cancer (LABC) post Neoadjuvant Chemotherapy (NAC).
    Al-Saleh K; Abd El-Aziz N; Ali A; Abo Zeed W; Salah T; Elsamany S; Rasmy A; El Farargy O; Husain S; Al-Rikabi A; Alsaeed E; Aldiab A; Abd El-Warith A
    Gulf J Oncolog; 2019 May; 1(30):33-42. PubMed ID: 31242980
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
    Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
    Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer.
    Kock L; Mahner S; Choschzick M; Eulenburg C; Milde-Langosch K; Schwarz J; Jaenicke F; Müller V; Woelber L
    Int J Gynecol Cancer; 2011 Jan; 21(1):141-8. PubMed ID: 21330838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy.
    Jarzab M; Kowal M; Bal W; Oczko-Wojciechowska M; Rembak-Szynkiewicz J; Kowalska M; Stobiecka E; Chmielik E; Tyszkiewicz T; Kaszuba M; Nowicka E; Lange B; Czarniecka A; Krajewska J; Dyla A; Dobrut M; Lange D; Jarzab B; Bobek-Billewicz B; Tarnawski R
    Folia Histochem Cytobiol; 2016; 54(4):202-209. PubMed ID: 28051275
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of neoadjuvant therapies in breast cancer with respect to pathological complete response, disease-free survival and overall survival: 15 years follow-up data from Kuwait.
    Krishnan Y; Al Awadi S; Sreedharan PS; Sujith Nair S; Thuruthel S
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e30-7. PubMed ID: 23937427
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High monocarboxylate transporter 4 protein expression in stromal cells predicts adverse survival in gastric cancer.
    Yan P; Li YH; Tang ZJ; Shu X; Liu X
    Asian Pac J Cancer Prev; 2014; 15(20):8923-9. PubMed ID: 25374230
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
    Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
    BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Carbonic anhydrase IX overexpression regulates the migration and progression in oral squamous cell carcinoma.
    Yang JS; Lin CW; Chuang CY; Su SC; Lin SH; Yang SF
    Tumour Biol; 2015 Dec; 36(12):9517-24. PubMed ID: 26130414
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
    Kuerer HM; Newman LA; Buzdar AU; Hunt KK; Dhingra K; Buchholz TA; Binkley SM; Ames FC; Feig BW; Ross MI; Hortobagyi GN; Singletary SE
    Am J Surg; 1998 Dec; 176(6):502-9. PubMed ID: 9926779
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy.
    Xin F; Yu Y; Yang ZJ; Hou LK; Mao JF; Xia L; Wang X; Cao XC
    Tumour Biol; 2016 Jun; 37(6):8445-54. PubMed ID: 26733172
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
    Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
    Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Herrada J; Iyer RB; Atkinson EN; Sneige N; Buzdar AU; Hortobagyi GN
    Clin Cancer Res; 1997 Sep; 3(9):1565-9. PubMed ID: 9815844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.